Reply to J.-G. Wang et al

Affiliations

¹ Patrick J. Leavey, MD, UT Southwestern Medical Center Dallas and Children's Health, Children's Medical, Center Dallas, Dallas, TX; Mark D. Krailo, PhD, University of Southern California, Los Angeles, CA; Steven G. DuBois, MD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA; Damon R. Reed, MD, Moffitt Cancer Center Adolescent and Young Adult Program, Tampa, FL; Katherine A. Janeway, MD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA; and Leo Mascarenhas, MD, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA.

Comment

Patrick J Leavey et al. J Clin Oncol. 2022.

. 2022 May 1;40(13):1507-1508.

doi: 10.1200/JCO.21.02922. Epub 2022 Mar 2.

¹ Patrick J. Leavey, MD, UT Southwestern Medical Center Dallas and Children's Health, Children's Medical, Center Dallas, Dallas, TX; Mark D. Krailo, PhD, University of Southern California, Los Angeles, CA; Steven G. DuBois, MD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA; Damon R. Reed, MD, Moffitt Cancer Center Adolescent and Young Adult Program, Tampa, FL; Katherine A. Janeway, MD, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA; and Leo Mascarenhas, MD, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA.

No abstract available

Comment on

Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.
Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Leavey PJ, et al. J Clin Oncol. 2021 Dec 20;39(36):4029-4038. doi: 10.1200/JCO.21.00358. Epub 2021 Oct 15. J Clin Oncol. 2021. PMID: 34652968 Free PMC article. Clinical Trial.
Regarding the Children's Oncology Group AEWS1031 Trial for Ewing Sarcoma.
Wang JG, Wei QF, Tang QM. Wang JG, et al. J Clin Oncol. 2022 May 1;40(13):1506. doi: 10.1200/JCO.21.02546. Epub 2022 Mar 2. J Clin Oncol. 2022. PMID: 35235371 No abstract available.

1. Wang J-G, Wei Q-F, Tang Q-M. Regarding the children's oncology group AEWS1031 trial for Ewing sarcoma. J Clin Oncol. 2022;40:1506. - PubMed
1. Leavey PJ, Laack NN, Krailo MD, et al. Phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic Ewing sarcoma: A Children's Oncology Group report J Clin Oncol 394029–40382021 - PMC - PubMed
1. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts Clin Cancer Res 53617–36311999 - PubMed
1. Hawkins DS, Bradfield S, Whitlock JA, et al. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study Pediatr Blood Cancer 47790–7942006 - PubMed
1. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors Pediatr Blood Cancer 47795–8002006 - PubMed